Prior to joining the company, Dr. Hartman held a number of executive level roles at AstraZeneca, most recently as vice president of Projects in Innovative Medicines. Other positions included vice president of Respiratory & Inflammation Research UK and vice president of Lead Generation DECS, a global science and technology group supporting early-stage projects in eight disease areas across 12 R&D sites. Prior to joining AZ, Dr. Hartman spent seven years at Hoffmann-La Roche in Basel, Switzerland, as a project leader and principal scientist in nervous system diseases.
Barbara S. Fox, Ph.D., chief executive officer of Avaxia, said, “Debbie has a strong track record of delivering new drugs into the clinic and managing early clinical development. In addition to leading research efforts on AVX-470, Debbie will expand our pipeline of gut-targeted oral antibody therapeutics through internal efforts and external collaborations. I would also like to thank Dan Tracey, our former vice president, Research, for his many contributions to Avaxia and to wish him well in his retirement. We are grateful that Dan will continue to support Avaxia as a consultant.”